Short Squeeze, page-148

Some participants on this forum show no attempt to research Mesoblast and share unresearched and bias views on the company, obviously here for a free education. But schooling takes time and effort that IMO lazy students doesn't deserve.

If they had done their research, and simply listened to the most recent quarterly call he would be well aware that Mesoblast are at the cusp of significant milestones which could result in a strong re-rate.

1. COVID ARDs trial is waiting on the Ryoncil BLA, but Mesoblast are working with the NIH to get this set up.

2. Second CLBP Phase 3 trial is planning and working out how large the trial needs to be etc, with 'strategic partners' ...

3. Ryoncil BLA resubmission is just around the corner, with the timing of the FDA review likely to be driven by how quickly they can complete the Singapore Lonza manufacturing facility

4. CHF FDA approval pathway meeting with the FDA also just around the corner, providing clarity on next steps.

5. Colitus Investigator lead phase 2 interim results were so good, an early stop may be recommended and will go straight to a pivotal phase 3 trial.All this and more if he had just listened to the most recent Mesoblast quarterly call.

Some posters are not really good at research when they try and do it on a company they own, let alone ones they don't.

For example on a clinical stage biotech, I said that company was underfunded for their two phase 3 trials and needed a cap raise, but some poster said they were fully funded and no cap raise required... guess what $75m equity facility announced earlier this year.... I said the recruitment and read-out were going to be delayed, some poster said they may surprise and finish recruitment early... guess what 9 month delay announced last week, now mid-late 2024.

There is an ignore function that I am using to avoid having to waste time educating people who makes no attempt to research Mesoblast.